What is SELLAS Life Sciences Group, Inc.'s (SLS) StockRank?

MoatMap's StockRank for SELLAS Life Sciences Group, Inc. (SLS) is 46/100, with a Hold signal. This is a composite score combining Quality (40), Value (22), and Momentum (74) factor ranks across MoatMap's 20,000+ stock universe.

Does SELLAS Life Sciences Group, Inc. have an economic moat?

SELLAS Life Sciences Group, Inc. (SLS) has a Quality factor score of 40/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is SELLAS Life Sciences Group, Inc. a buy, hold, or sell?

MoatMap's current signal for SELLAS Life Sciences Group, Inc. (SLS) is Hold, based on a StockRank of 46/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is SELLAS Life Sciences Group, Inc. in?

SELLAS Life Sciences Group, Inc. (SLS) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

SLS

HOLDREMOVE

SELLAS Life Sciences Group, Inc. · Healthcare · United States · $1.7B · Avg Vol: $81M/d

StockRank

P/E (TTM)

—

ROE

-43.6%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

SELLAS Life Sciences is a highly speculative clinical-stage biopharmaceutical company with no proven commercial products or pricing power. It fails our quality filters completely, representing a binary regulatory bet rather than a high-conviction compounder.

COMPANY DESCRIPTION

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on novel cancer immunotherapies. The company's competitive moat is its lead product candidate, galinpepimut-S (GPS), a WT1-targeting immunotherapy designed to address a wide range of hematologic malignancies and solid tumors. It operates as a niche biotechnology developer targeting unmet needs in oncology.

FINANCIAL SUMMARY (USD)

Year	2021	2022	2023	2024	2025	CAGR
Revenue	—	1.0M	0	0	0	—
EPS	—	-0.23	-0.22	-0.19	-0.25	—
Shares	—	196.6M	196.6M	196.6M	153.1M	-22.1%
Debt	—	0.9M	0.9M	1.0M	1.0M	1.9%
Equity	—	4.9M	-8.0M	9.5M	70.9M	144.5%
Op CF	—	-23.8M	-31.4M	-35.4M	-28.4M	—
Inv CF	0	-4.5M	-5.5M	0	—	—
Fin CF	—	24.1M	22.3M	46.8M	86.3M	—

PRICE (1Y)+63.3%

SMA 50SMA 200

$8.05

RSI (14)

38.2

52W High

$9.51

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

-39.6%17.3

ROE

-43.6%19.6

GP/Assets

—N/A

Op. Margin

0.0%40.4

FCF/Assets

-22.5%14.6

Piotroski

—28.7

Int. Cover

—N/A

D/E Ratio

0.01x89.9

Current Ratio

17.22x94.0

Value

P/E (TTM)

—N/A

EV/EBITDA

—N/A

P/FCF

—N/A

P/B

13.2x7.6

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

85%80.8

RS 6M

255%99.4

SMA 50/200

1.67x99.1

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+35%45.4

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$1.7B

P/E (Forward)

-52.2x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SLS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
SLS	SELLAS Life Sciences Group, Inc.(you)	$1.7B	46	HOLD
ARDX	Ardelyx, Inc.	$1.5B	46	HOLD
CAPR	Capricor Therapeutics, Inc.	$1.7B	43	HOLD
RAPP	Rapport Therapeutics, Inc.	$1.9B	47	HOLD
IOVA	Iovance Biotherapeutics, Inc.	$1.9B	49	HOLD
ANAB	AnaptysBio, Inc.	$1.7B	51	HOLD
FTRE	Fortrea Holdings Inc.	$1.4B	48	HOLD
TYRA	Tyra Biosciences, Inc.	$1.9B	41	HOLD
VIR	Vir Biotechnology, Inc.	$1.6B	53	HOLD
AVBP	ArriVent BioPharma, Inc.	$1.3B	43	HOLD

Peer medians: ROE -22.4% · P/E 25.3x · Gross margin 44.3%

SELLAS Life Sciences Group, Inc. (SLS) — Stock Score Summary

SELLAS Life Sciences Group, Inc. (SLS) has a MoatMap StockRank of 46/100 based on Quality (40/100), Value (22/100), and Momentum (74/100) factor scores. The current signal is HOLD. SELLAS Life Sciences is a highly speculative clinical-stage biopharmaceutical company with no proven commercial products or pricing power. It fails our quality filters completely, representing a binary regulatory bet rather than a high-conviction compounder.

Key Financial Metrics

Price	$8.05
Market Cap	$1.7B
P/E (Forward)	-52.20
Price/Book	13.23
Return on Equity	-43.6%
Return on Invested Capital	-39.6%
Debt/Equity	0.81
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-18M

SELLAS Life Sciences Group, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is SELLAS Life Sciences Group, Inc.’s (SLS) StockRank?: MoatMap’s StockRank for SELLAS Life Sciences Group, Inc. (SLS) is 46/100, with a Hold signal. It is a composite of Quality (40), Value (22), and Momentum (74) factor ranks across MoatMap’s 20,000+ stock universe.
Does SELLAS Life Sciences Group, Inc. have an economic moat?: SELLAS Life Sciences Group, Inc. (SLS) has a Quality factor score of 40/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is SELLAS Life Sciences Group, Inc. a buy, hold, or sell?: MoatMap’s current signal for SELLAS Life Sciences Group, Inc. (SLS) is Hold, based on a StockRank of 46/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is SELLAS Life Sciences Group, Inc. in?: SELLAS Life Sciences Group, Inc. (SLS) operates in the Healthcare sector, specifically the Biotechnology industry (United States).